Form 4: Apogee Therapeutics Grants Stock Options to Chief Medical Officer

Apogee Therapeutics has granted stock options to its Chief Medical Officer, Carl Dambkowski, for the purchase of 124,962 shares of common stock.

Summary

• Apogee Therapeutics granted stock options to Carl Dambkowski, the company's Chief Medical Officer.
• The options allow Dambkowski to purchase 124,962 shares of Apogee's common stock.
• The options vest in 48 equal monthly installments over a four-year period from the grant date, contingent on his continued service to the company.
• The grant was made on December 9, 2024, at a price of $49.07 per share.

Sentiment

Score: 7

Explanation: The document reflects a standard business practice of granting stock options to executives, which is generally viewed positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The stock option grant aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of Apogee's stock price.
• If the executive leaves the company before the options fully vest, they may forfeit some or all of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The four-year vesting period is typical for such grants, aligning with long-term value creation.
• The number of shares granted is likely based on the executive's role and the company's overall compensation strategy, which is common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, executive compensation, vesting, common stock, Apogee Therapeutics, Carl Dambkowski, Chief Medical Officer